Skip to main content
AdvisorShares Psychedelics ETF—— (—)Compass Pathways—— (—)Definium Therapeutics—— (—)GH Research—— (—)Helus Pharma—— (—)MIRA Pharmaceuticals—— (—)Neuphoria Therapeutics—— (—)Eli Lilly—— (—)Johnson & Johnson—— (—)AbbVie—— (—)Otsuka Pharmaceutical—— (—)Numinus Wellness—— (—)Optimi Health—— (—)PharmAla Biotech—— (—)Enveric Biosciences—— (—)Incannex Healthcare—— (—)Aurora Cannabis—— (—)Cronos Group—— (—)SNDL—— (—)Bright Minds Biosciences—— (—)PharmaTher Holdings—— (—)IM Cannabis—— (—)MariMed—— (—)Vireo Growth—— (—)
Loading prices
Back to the NewsWire

Biospace

Published November 16, 2026 · Updated November 17, 2026

Helus Pharma Announces Positive Topline Results from Phase 3 APPROACH Study ... - BioSpace

Read the full story at Biospace

Serious adverse events mar robust efficacy data for Helus' psychedelic in major depression ... Submit a Press Release · Submit an Event. © 1985 - 2026.

Surfaced by this Google Alert

  • Psychedelic press release